Compare Charles River Laboratories Intl. Inc (CRL) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Utilities Select Sector SPDR Fund — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Utilities Select Sector SPDR Fund trades at $43.9. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| CRL | XLU | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | — |
52-Week High | $282.00 | $47.73 |
52-Week Low | $145.57 | $41.31 |
Enterprise Value | $16.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
XLU, the Utilities Select Sector SPDR Fund, trades at $43.85, up 1.65% on the day, but technical indicators signal a bearish trend with moving averages showing strong sell signals. The ETF is positioned to benefit from AI-driven power demand, with recent news highlighting increased call option activity and its role as a defensive income play with a dividend scheduled for June 2026. However, key financial ratios like P/E and ROE are unavailable from the provided data.
The outlook for XLU is mixed; AI power demand offers growth potential, but technical weakness and lack of current fundamental metrics pose risks. Investors should weigh the defensive income characteristics against bearish technical signals and evolving sector dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
